Nature Communications (Oct 2022)

Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

  • Clovis A. Silva,
  • Ana C. Medeiros-Ribeiro,
  • Leonard V. K. Kupa,
  • Emily F. N. Yuki,
  • Sandra G. Pasoto,
  • Carla G. S. Saad,
  • Solange R. G. Fusco,
  • Rosa M. R. Pereira,
  • Samuel K. Shinjo,
  • Ari S. R. Halpern,
  • Eduardo F. Borba,
  • Fernando H. C. Souza,
  • Lissiane K. N. Guedes,
  • Renata Miossi,
  • Karina R. Bonfiglioli,
  • Diogo S. Domiciano,
  • Andrea Y. Shimabuco,
  • Danieli C. O. Andrade,
  • Luciana P. C. Seguro,
  • Ricardo Fuller,
  • Percival D. Sampaio-Barros,
  • Ana P. L. Assad,
  • Julio C. B. Moraes,
  • Claudia Goldenstein-Schainberg,
  • Henrique A. M. Giardini,
  • Henrique C. Silva,
  • Victor A. O. Martins,
  • Lorena E. B. Villamarin,
  • Renata S. Novellino,
  • Lucas P. Sales,
  • Carlo S. R. Araújo,
  • Matheus S. R. Silva,
  • Dilson M. N. Filho,
  • Marta H. Lopes,
  • Alberto J. S. Duarte,
  • Esper G. Kallas,
  • Nadia E. Aikawa,
  • Eloisa Bonfa

DOI
https://doi.org/10.1038/s41467-022-33042-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Characterising the response to SARS-CoV-2 post vaccination is critical in the appraisement of the induced immune response, performance and protective potential. Here the authors present data from a phase 4 clinical trial in autoimmune rheumatic disease patients 6 months post second dose of Sinovac-CoronaVac inactivated vaccine that show a marked reduction in antibody particularly in males or those under treatment with immune targeting therapies but saw no rise in COVID-19 disease.